CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN
K-001-201
Phase 2 small_molecule active
Quick answer
CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN for Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active